Twist Bioscience Corporation (TWST) News
Track canonical SquawkNews coverage tagged to TWST, Twist Bioscience Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Twist Bioscience shares rise after deal with Lilly’s TuneLab
Twist Bioscience said it signed a deal with Eli Lilly’s drug discovery platform Lilly TuneLab, sending TWST up 5% to $144.90 Wednesday. The stock has more than quadrupled over the past year.
EQUITY | Sep 16, 2026, 04:01 PM UTC
H
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Nasdaq Composite gaining around 150 points on Wednesday. Shares of LuxExperience BV-ADR (NYSE: LUXE ) rose sharply after the company reported fourth-quarter results. LuxExperience reporte
LIVE | Sep 16, 2026, 01:57 PM UTC
L
Cathie Wood Makes Striking Switch Between AI Stock Giants
Cathie Wood's Ark Invest made a sharp rotation across technology and biotechnology stocks last week, buying roughly $28 million of Meta Platforms NASDAQ:META while selling a nearly identical dollar amount of Alphabet NAS
EQUITY | Sep 15, 2026, 12:21 PM UTC
L
TWST price target set at $45 by BWS Financial
EQUITY | Sep 09, 2026, 09:46 PM UTC
L
UBS initiates Twist Bioscience at neutral; sets $144 target
UBS initiated Twist Bioscience at neutral and announced a $144.00/share price target.
EQUITY | Sep 09, 2026, 01:36 PM UTC
L
TWST to Present at Baird 2026 Global Healthcare Conference
Twist Bioscience (TWST) will present at Baird 2026 Global Healthcare Conference.
EQUITY | Sep 09, 2026, 12:05 PM UTC
L
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
AUSTIN, Texas, Sept. 3, 2026 // -- Equity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton values the global AI in drug dis
EQUITY | Sep 03, 2026, 12:55 PM UTC
L
Cathie Wood Drops $124 Million on AI Stocks, Dumps AMD
Cathie Wood Drops $124 Million on AI Stocks, Dumps AMD
EQUITY | Sep 01, 2026, 01:46 AM UTC
L
Twist Bioscience named Anthropic independent evaluator in 8-K
Twist Bioscience says in an 8-K that Anthropic chose the company as one of its independent evaluators to rapidly produce and test AI-designed proteins for binding.
MNA | Aug 19, 2026, 04:56 PM UTC
H
Twist Bioscience Launches $250 Million Stock Offering
Twist Bioscience proposes public offering of common stock
EQUITY | Aug 04, 2026, 08:01 PM UTC
L
Twist Bioscience Sees AI Drug Discovery Pipeline Expand
Twist Bioscience Corporation (NASDAQ: TWST ) stock is up on Monday as the company reported its fiscal 2026 third-quarter financial results and raised fiscal 2026 guidance. The life science company reported an adjusted lo
EARNINGS | Aug 03, 2026, 04:13 PM UTC
L
TWST Twist Bioscience RESULTS: Q3, Q3 REV $118.4M vs. EST $114.5M, Q3 EPS $-0.56, Twist Bioscience Earnings Notes:, Outlook FY REV $456-457M
TWST Twist Bioscience RESULTS: Q3, Q3 REV $118.4M vs. EST $114.5M, Q3 EPS $-0.56, Twist Bioscience Earnings Notes:, Outlook FY REV $456-457M, Outlook Q4 total REV of approximately $123M to $124M, Outlook Q4 to achieve AD
EARNINGS | Aug 03, 2026, 11:21 AM UTC
L
Twist Bioscience Raises FY2026 Sales Guidance from $442.000M-$447.000M to $456.000M-$457.000M vs $446.103M Est
Twist Bioscience (NASDAQ: TWST ) raises FY2026 sales outlook from $442.000 million-$447.000 million to $456.000 million-$457.000 million vs $446.103 million estimate.
EARNINGS | Aug 03, 2026, 11:18 AM UTC
L
TWST - Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results
TWST - Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results
EARNINGS | Aug 03, 2026, 11:17 AM UTC
H
Implied EPS movers for Monday AM: MAR +/-0.9%, KRYS +/-11.5%, TSN +/-6.6%, TGTX +/-12.0%, TWST +/-18.9%, L +/-4.3%, HESM +/-5.2%, CNH +/-8.0
Implied EPS movers for Monday AM: MAR +/-0.9%, KRYS +/-11.5%, TSN +/-6.6%, TGTX +/-12.0%, TWST +/-18.9%, L +/-4.3%, HESM +/-5.2%, CNH +/-8.0%, MMYT +/-11.7%, CNA +/-5.7%, SRAD +/-13.5%, AVA +/-6.4%, ABTC +/-14.7%, SBH +/
EARNINGS | Jul 31, 2026, 06:05 PM UTC
M
Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $107
Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ: TWST ) with a Buy and raises the price target from $60 to $107.
EQUITY | Jun 29, 2026, 02:05 PM UTC
M
TWST: Barclays Raises PT
Barclays maintains overweight rating on Twist Bioscience and raises price target to $95
EQUITY | Jun 24, 2026, 02:55 PM UTC
L
TWST Files Mixed Shelf
TWST files a mixed shelf offering with the SEC
EQUITY | Jun 18, 2026, 08:10 PM UTC